Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Telix Pharmaceuticals ( (AU:TLX) ) is now available.
Challenger Limited has notified the Australian Securities Exchange that it and its associated entities have ceased to be substantial holders in Telix Pharmaceuticals. The change in holding status was formalised via a statutory notice of ceasing to be a substantial holder, indicating Challenger’s voting interest in Telix has fallen below the substantial holding threshold.
The move reduces institutional ownership by Challenger in Telix and may slightly alter the biotech group’s shareholder register composition. While the notice does not detail the transactions or reasons, the exit of a substantial holder can influence market perceptions of Telix’s investor base and may prompt attention from other institutional or strategic investors.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a biotechnology company focused on developing and commercialising radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. The company operates in the healthcare and life sciences sector, targeting global markets for precision oncology and molecular imaging solutions.
Average Trading Volume: 3,129,864
Technical Sentiment Signal: Sell
Current Market Cap: A$4.39B
For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.